

Ethan Jin

Partner



ethan.jin@cooley.com

+86 21 6030 0698

+86 10 8540 0658

Beijing

Capital Markets

Corporate Governance and Securities Regulation

Emerging Companies

Mergers and Acquisitions

Ethan Jin represents clients on securities and corporate transactions in the Greater China region, including Hong Kong IPOs, pre-IPO private equity investments, investments in and corporate governance of HKEX-listed companies, private placements, public and private M&A and compliance. He advises clients on a wide array of industries and has led the execution of dozens of Hong Kong IPOs, representing both issuers and underwriters. He also has experience advising on foreign direct investments in China.

From 2001 to 2004, Ethan practiced PRC law in respect of foreign direct investment in China. He is one of the few Hong Kong capital market lawyers who are familiar with the corporate legal practice of both Hong Kong and Mainland China.

Ethan is a native Mandarin speaker and is fluent in English.

Representative Matters and Clients:*Capital Markets*

- **CICC, Citigroup and Merrill Lynch (Asia Pacific) in Fenbi's** HK\$198 million Hong Kong IPO and global offering
- **Genertec Universal Medical Group Company Limited** in its \$150 million issue of convertible bonds and \$150 million share placing
- **Sequoia China** in its cornerstone investment in **Linklogis, JOINN Laboratories, Antengene**, etc.
- **Zhongguancun Science-Tech Leasing** in its HK\$507 million Hong Kong IPO and global offering
- **Haitong International and BOCOM International** and the other underwriters in **China Bright Culture Group's** HK\$904 million Hong Kong IPO and global offering
- **WuXi Biologics** in its \$510 million Hong Kong IPO and global offering
- **Rici Healthcare Holdings Limited** in its HK\$1.07 billion Hong Kong IPO and global offering
- **Universal Medical Financial & Technical Advisory Services Company Limited** in its HK\$4.2 billion Hong Kong IPO and global offering
- **Tonic Industries Holdings Limited** in its reverse takeover of HK\$6,688 million of property assets and business from China Merchants Property Development Co., Ltd. and its deemed new listing on the HKEX
- **China Pacific Insurance (Group) Co., Ltd** in its \$1.34 billion placing of H shares
- **Huadian Fuxin Energy Corporation Limited** in its HK\$2.50 billion Hong Kong IPO and global offering

- **Haitong Securities Co., Ltd.** in its \$1.67 billion Hong Kong IPO and global offering
- **Morgan Stanley** in **Hilong Holding Limited's** \$129 million Hong Kong IPO and global offering
- **J.P. Morgan** in **China Hongqiao Group Limited's** \$822 million Hong Kong IPO and global offering
- **Sateri Holdings Limited** in its \$430 million Hong Kong IPO and global offering arranged by Credit Suisse and Morgan Stanley
- **BOCI** and **UBS** in **Sinotrans Shipping Limited's** \$1.47 billion Hong Kong IPO and global offering

Mergers and Acquisitions

- **PW Medtech (HKSE: 1358)** as Hong Kong legal counsel in its \$513 million share exchange with CBPO (NASDAQ: CBPO), which constituted a very substantial disposal and a very substantial acquisition for PW Medtech
- **Yingde Gases** and its second largest shareholder, in a series of transactions including board restructuring, share placing, hostile takeover, shareholder dispute, SFC regulatory investigation and \$2.7 billion privatization of Yingde Gases
- **Joined offerors (Sequoia and the founder)** in the HK\$1.49 billion privatization of Dongpeng Holdings by way of scheme of arrangement
- **Haitong International Securities Group Limited** in its capitalization issue to and an offer for sale by its controlling shareholder
- **China Hengtian Group** in its takeover of Fong's Industries Company Limited, a HKEX-listed company
- **Iron Mining International Limited** in a secured convertible loan of \$700 million granted by China Investment Corporation
- **Air China Limited** in its acquisition of a 12.5 percent interest in Cathay Pacific from CITIC Pacific with a value of \$817 million
- **Air China Limited** in its strategic acquisition of a 17.5 percent interest in Cathay Pacific, disposal of its interests in Dragonair, and a strategic investment by Cathay Pacific in Air China with aggregate value of \$2.4 billion

HKEX compliance clients

- Genertec Universal Medical Group Company Limited
- Rici Healthcare Holdings Limited
- PW Medtech Group Limited
- PetroChina Company Limited
- Air China Limited
- China Pacific Insurance (Group) Co., Ltd.

Education

Stanford Law School

LLM, Corporate Governance and Practice, 2005

Peking University Law School

LLM, 2001

Peking University Law School

LLB, 1998

Admissions & Credentials

New York

Solicitor of Hong Kong